Kyverna Therapeutics reported one-year data supporting its autoimmune CAR-T submission for stiff person syndrome, with the company presenting long-term autoimmune benefit in the ongoing development effort. The condition affects an estimated 6,000 patients in the U.S., according to the company’s update. The company’s messaging emphasizes durability alongside a safety profile designed to address concerns that have slowed autoimmune CAR-T programs elsewhere in the category. While CAR-T therapy has established efficacy in oncology, autoimmune indications remain a higher bar due to relapse dynamics and immune safety risk. For the field, the read-through is that FDA submissions for autoimmune CAR-T will increasingly lean on sustained clinical benefit signals, not just early response.